针对癌症治疗中的cuproptosis:机制性见解和临床前景
Chenliang Zhang1, Tingting Huang2, Liping Li3
1Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China. zhangchenliang@wchscu.edu.cn.
Journal of hematology & oncology
|August 16, 2024
概括
超量铜引发的一种新型细胞死亡途径cuproptosis在癌症治疗中表现有前途. 针对这种机制可以克服对现有癌症治疗方法的耐药性.
科学领域:
- 细胞生物学 细胞生物学
- 生物化学 生物化学
- 在瘤学瘤学.
背景情况:
- cuproptosis是一种新发现的细胞死亡机制.
- 它是由细胞内过度积累的铜引起的.
- cuproptosis涉及线粒体功能障碍和蛋白质毒性压力.
研究的目的:
- 为了审查cuproptosis的机制.
- 探索其在癌症治疗中的作用.
- 讨论诱导瘤中cuproptosis的策略.
主要方法:
- 关于cuproptosis机制的文献综述.
- 针对cuproptosis的治疗策略的分析.
- 讨论癌症中的代谢和遗传向.
主要成果:
- 质死是由二利波胺 S-乙转移酶的铜诱导的聚合引起的.
- 它与三碳酸循环和铁-硫集群损失有关.
- 诸如离子体,小化合物和纳米医学等各种药物可以诱导cuproptosis.
结论:
- 质亡为癌症提供了一个潜在的治疗策略.
- 向cuproptosis可以克服对化疗和免疫疗法的耐药性.
- 对cuproptosis的进一步研究有望为新的瘤疗法提供希望.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K


